Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Savior LifetecROCO:4167 -0.24%68 EBITDA Margin % is 34.29% as of Dec. 2025, which is 77% above its 10-year median of 19.42. GuruFocus rates ROCO:4167 with a GF Score™ of 68/100 and a GF Value™ of NT$20.31 (Fairly Valued). The stock has 4 warning signs investors should review. Among 939 Biotechnology companies, Savior Lifetec ranks better than 94.57% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Savior Lifetec's EBITDA for the
three
months ended in Dec. 2025 was NT$110 Mil. Savior Lifetec's Revenue for the
three
months ended in Dec. 2025 was NT$320 Mil. Therefore, Savior Lifetec's EBITDA margin for the quarter that ended in Dec. 2025 was 34.29%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Savior Lifetec EBITDA Margin % Related Terms
Savior Lifetec EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Savior Lifetec's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4167 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Savior Lifetec's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Savior Lifetec EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Savior Lifetec's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Savior Lifetec's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Savior Lifetec (ROCO:4167) has a EBITDA Margin % of 34.29% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Savior Lifetec and its competitors. This is 77% above median its historical median of 19.42. According to the industry distribution chart, Savior Lifetec ranks #51 out of 939 companies in the Biotechnology industry, placing it in the top 5.4%.
Is Savior Lifetec's EBITDA Margin % too high?
Savior Lifetec's current EBITDA Margin % of 34.29% is 77% above median its 10-year median of 19.42. Based on the distribution chart, Savior Lifetec ranks #51 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Savior Lifetec has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Savior Lifetec's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Savior Lifetec ranks #51 out of 939 companies for EBITDA Margin %. This places Savior Lifetec in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Savior Lifetec and its competitors. Savior Lifetec's current EBITDA Margin % is 34.29%, which is 77% above median its own 10-year median of 19.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Savior Lifetec stock overvalued right now?
Based on GuruFocus' analysis, Savior Lifetec (ROCO:4167) is currently considered Fairly Valued. The stock's GF Value™ is NT$20.31, compared to a current price of NT$20.60 — trading 1.4% above its estimated fair value. The current EBITDA Margin % is 34.29%, which is 77% above median its 10-year median of 19.42. Savior Lifetec's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Savior Lifetec (ROCO:4167), the current EBITDA Margin % is 34.29% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Savior Lifetec (ROCO:4167) Overvalued in 2026?
Based on GuruFocus' analysis, Savior Lifetec stock appears to be overvalued.
The current stock price of NT$20.60 is trading 1.4% above its estimated GF Value™ of NT$20.31.
GuruFocus considers Savior Lifetec to be Fairly Valued.
Key valuation signals for ROCO:4167:
EBITDA Margin %: 34.29% (77% above median its 10-year median of 19.42)
GF Value™: NT$20.31 vs. price of NT$20.60 (1.4% above fair value)
No single metric tells the full story. See the ROCO:4167 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Savior Lifetec Corp is engaged in the research, development, design, manufacture, and sale of carbapenem generics, injection generics, controlled-release generics, development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms of the aforementioned products. The company also provides medicine manufacturer technology and services. The company geographically operates in four regions: the Americas, Asia, Taiwan, and Europe.
68GF Score
Get the complete analysis for ROCO:4167
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4167 has been successfully added to your 
